6L60 Stock Chart & Stats
€5.55
--
Market closed
€5.55
--
Day’s Range― - ―
52-Week Range€4.06 - €9.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€244.60M
Enterprise Value€292.82M
Total Cash (Recent Filing)€64.64M
Total Debt (Recent Filing)€43.14M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Aug 06, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding52,202,965
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.77
Price to Sales (P/S)6.53
P/FCF Ratio-3.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.88Price Target Upside168.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.06
Revenue Forecast (FY)€53.65M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue & DTC GrowthSustained, high single‑digit to double‑digit top‑line growth and a rapidly scaling DTC channel signal durable product-market fit and distribution control. A larger DTC mix improves customer acquisition scale and data capture, supports recurring reorders and retention, and underpins multi-channel commercial expansion.
Product Pipeline & DifferentiationA roadmap to year-long sensors (Gemini, Freedom) and built-in connectivity represents a durable competitive advantage: fewer replacements, stronger retention, and differentiated integrations (AID) improve unit economics, payer conversations and HCP uptake over multiple years if clinical goals are met.
Strengthened Liquidity & Funding CapacityA meaningful equity raise plus an enlarged, multi‑tranche Hercules facility materially extend runway to fund commercialization and pivotal trials. This structural improvement in financing capacity reduces immediate liquidity pressure and supports execution on commercial and clinical milestones over the next 12–24 months.
Bears Say
Persistent Cash BurnLarge and persistent negative operating and free cash flow creates a structural need for external capital to sustain growth. Even with improved revenue, the projected 2026 cash utilization implies continued dilution or debt draws if execution slips, constraining strategic optionality and raising financing dependence risk.
Elevated Leverage & Weakened EquityRising leverage and declining equity reduce balance sheet flexibility and increase refinancing and covenant risk. Higher debt levels amplify interest and repayment pressures if revenue or margin ramps slow, making the company more sensitive to execution delays and less able to absorb shocks without dilutive financing.
High Operating Expense RampA deliberate SG&A ramp to internalize U.S. commercialization sharply increases fixed costs and near‑term losses. If DTC economics, HCP adoption or retention underperform expectations, the higher cost base could compress margins and accelerate cash burn, making profitability and self‑funding more distant.
Senseonics Holdings News
6L60 FAQ
What was Senseonics Holdings Inc.’s price range in the past 12 months?
Senseonics Holdings Inc. lowest stock price was €4.06 and its highest was €9.60 in the past 12 months.
What is Senseonics Holdings Inc.’s market cap?
Senseonics Holdings Inc.’s market cap is €244.60M.
When is Senseonics Holdings Inc.’s upcoming earnings report date?
Senseonics Holdings Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Senseonics Holdings Inc.’s earnings last quarter?
Senseonics Holdings Inc. released its earnings results on May 07, 2026. The company reported -€0.622 earnings per share for the quarter, missing the consensus estimate of -€0.601 by -€0.021.
Is Senseonics Holdings Inc. overvalued?
According to Wall Street analysts Senseonics Holdings Inc.’s price is currently Undervalued.
Does Senseonics Holdings Inc. pay dividends?
Senseonics Holdings Inc. does not currently pay dividends.
What is Senseonics Holdings Inc.’s EPS estimate?
Senseonics Holdings Inc.’s EPS estimate is -0.54.
How many shares outstanding does Senseonics Holdings Inc. have?
Senseonics Holdings Inc. has 52,202,965 shares outstanding.
What happened to Senseonics Holdings Inc.’s price movement after its last earnings report?
Senseonics Holdings Inc. reported an EPS of -€0.622 in its last earnings report, missing expectations of -€0.601. Following the earnings report the stock price went up 2.294%.
Which hedge fund is a major shareholder of Senseonics Holdings Inc.?
Currently, no hedge funds are holding shares in DE:6L60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Senseonics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€14.88 (168.05% Upside)
€14.88 (168.05% Upside)
Blogger Sentiment
Bullish
DE:6L60 Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth €110.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.74%
12-Months-Change
Fundamentals
Return on Equity
-130.00%
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Senseonics Holdings Inc.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
6L60 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial momentum and validating financial results: Q1 revenue of $11.7M (up 85% YoY), a 58% gross margin, rapid DTC growth (~100% YoY) and successful U.S. commercial integration. Management raised 2026 revenue guidance to $60M–$64M (70%–82% growth) and advanced pipeline milestones (Gemini and Freedom) while adding substantial growth capital ($92M equity + expanded $140M credit facility with a $20M draw). Offsetting these positives are materially higher operating expenses and an expanded net loss driven by in‑house commercialization, significant planned cash burn ($110M–$120M for 2026), increased debt, and remaining execution risk in the European transition and competitive landscape. On balance, the highlights from stronger-than-expected top-line performance, margin expansion and financing to fund growth outweigh the near-term cost and cash challenges, but execution through the rest of 2026 will be key.View all DE:6L60 earnings summaries6L60 Stock 12 Month Forecast
Average Price Target
€14.88
▲(168.05% Upside)
Options Prices
Currently, No data available
---